SAMSUNG-ELECTRONICS
22.11.2021 10:02:09 CET | Business Wire | Press release
Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today announced that five of its memory products achieved global recognition for successfully reducing its carbon emission, while 20 additional memory products received carbon footprint certification. Samsung’s automotive LED packages also had their carbon footprint verification, a first in the industry for automotive LED packages, further expanding Samsung’s portfolio of eco-conscious ‘green chips’.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211122006067/en/
“It is exciting to see our environmentally sustainable efforts receiving global acknowledgements,” said Seong-dai Jang, Senior Vice President and Head of DS Corporate Sustainability Management Office at Samsung Electronics. “We will continue our path towards a sustainable future with ‘greener’ chips enabled by Samsung’s cutting-edge technology.”
Five memory products achieve the Carbon Trust ‘Reducing CO2’ certification
Five Samsung memory products – HBM2E (8GB), GDDR6 (8Gb), UFS 3.1 (512GB), Portable SSD T7 (1TB), microSD EVO Select (128GB) – recently earned ‘Reducing CO2’ labels from the Carbon Trust. The previous versions of the five products had received the ‘CO2 Measured’ certification from the Carbon Trust last year. The Carbon Trust recently also certified the product carbon footprints of 20 memory products1 by giving them the ‘CO2 Measured’ product carbon footprint label.
The Carbon Trust is an independent and expert partner of organizations that advises businesses on their opportunities in a sustainable, low-carbon world. The Carbon Trust also certifies the environmental footprint of organizations, supply chains and products.
The Reducing CO2 label certifies that a product’s carbon emission has decreased. Samsung was able to cut the carbon emission of the five memory products through enhanced production efficiency. This means that less electricity and raw materials were used per chip. For the Portable SSD T7 (1TB), Samsung used environmentally sustainable paper instead of plastic as packaging material to minimize the carbon footprint of the product.
Samsung estimates that the volume of carbon emissions reduced from the five products, after their release until July 2021, amounts to approximately 680,000 metric tons of CO2, which is equivalent to 11.3 million urban tree seedlings grown for ten years or the greenhouse gas emitted from 149,000 cars driven for one year.
Before a product can be certified for carbon reduction, its current carbon footprint must be validated in order to set the starting line for measuring carbon footprint changes. The CO2 Measured label verifies the current carbon emission of the product with a globally recognized specification (PAS 2050). Thus, the 20 Samsung memory products with the CO2 Measured label has now set the benchmark for future carbon reduction.
“We have certified five of Samsung’s memory chip products with the CO2 Reducing label, and are pleased to bring on board 20 more products with the CO2 Measured label,” said Hugh Jones, Managing Director at the Carbon Trust Advisory. “We hope that Samsung’s efforts could spread out to the entire semiconductor industry, so that the industry can continue its journey towards a more sustainable future.”
Carbon footprint of C-series 3W Automotive LEDs verified by UL
Four C-series 3W Automotive LED packages manufactured by Samsung – Gen3 (third generation) 3W White, Gen3 3W Amber, Gen2 (second generation) 3W White, and Gen2 3W Amber – received verification of their carbon footprint to ISO 14064-3 by UL.
UL, the global safety science leader, provides testing, inspection and certification, advisory and risk management services, decision-making tools, training and business intelligence offerings to help customers based in more than 100 countries solve critical business challenges, achieve sustainability goals, and prepare for future opportunities.
Since Samsung’s C-series 3W Automotive LED packages are energy efficient products that draw less power but produces more light output, they reduce carbon emissions of cars by improving energy efficiency and ensure longer driving range for electric vehicles in a single charge.
“UL congratulates Samsung for pursuing carbon footprint verification for their four C-series 3W Automotive LED packages, which will help automotive manufacturers select products with transparent, verified information about their environmental footprint,” said Doug Lockard, Vice President and General Manager of UL’s Retail and Consumer Products group. “By understanding the carbon impact of products, manufacturers like Samsung can work to reduce those impacts and improve the environmental performance of products over time.”
# # #
About Samsung Electronics Co., Ltd.
Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at http://news.samsung.com
.
1 SODIMM(8GB/16GB), LPDDR5(8GB/12GB/16GB), RDIMM(16GB/32GB), 980 PRO SSD(250GB/500GB/1TB/2TB), HBM2E(16GB), GDDR6(16Gb), UFS 3.1(128GB/256GB), microSD EVO Select(64GB/256GB/512GB), Portable SSD T7(500GB/2TB)
View source version on businesswire.com: https://www.businesswire.com/news/home/20211122006067/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 08:00:00 CET | Press release
Clinical and preclinical presentations reflect the company’s ongoing exploration of peripheral neuropathic pain Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greates
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
